Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02768805
Recruitment Status : Completed
First Posted : May 11, 2016
Last Update Posted : June 11, 2020
Sponsor:
Information provided by (Responsible Party):
Medicago

Tracking Information
First Submitted Date  ICMJE April 1, 2016
First Posted Date  ICMJE May 11, 2016
Last Update Posted Date June 11, 2020
Study Start Date  ICMJE March 2, 2016
Actual Primary Completion Date May 17, 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 11, 2016)
Immunogenicity assessed by the geometric mean titers (GMT) of hemagglutination inhibition (HI) antibody against the homologous influenza strains [ Time Frame: 21 days after injection ]
Immunogenicity will be assessed by the geometric mean titers (GMT) of hemagglutination inhibition (HI) antibody against the homologous influenza strains
Original Primary Outcome Measures  ICMJE
 (submitted: May 9, 2016)
Immunogenicity assessed by assessed by the geometric mean titers (GMT) of hemagglutination inhibition (HI) antibody against the homologous influenza strains [ Time Frame: 21 days after injection ]
Immunogenicity will be assessed by the geometric mean titers (GMT) of hemagglutination inhibition (HI) antibody against the homologous influenza strains
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 11, 2016)
  • Immunogenicity assessed by GMT of HI antibody against heterologous strains [ Time Frame: 21 days after injection ]
    Immunogenicity will be assessed by GMT of HI antibody against heterologous strains
  • Immunogenicity assessed by GMT of microneutralization (MN) antibody against homologous and heterologous strains [ Time Frame: 21 days after injection ]
    Immunogenicity will be assessed by GMT of microneutralization (MN) antibody against homologous and heterologous strains
  • Immunogenicity assessed by GMT of single radial hemolysis (SRH) antibody against homologous and heterologous strains [ Time Frame: 21 days after injection ]
    Immunogenicity will be assessed by GMT of single radial hemolysis (SRH) antibody against homologous and heterologous strains
  • Immunogenicity assessed by cell-mediated immune (CMI) response against homologous and heterologous strains [ Time Frame: 21 days after injection ]
    Immunogenicity will be assessed by cell-mediated immune (CMI) response against homologous and heterologous strains
  • Incidence of Solicited Local and Systemic Reactions [ Time Frame: 21 days after injection ]
  • Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: 21 days after injection ]
  • Incidence of Abnormal Clinical Laboratory Tests [ Time Frame: 3 days after injection ]
Original Secondary Outcome Measures  ICMJE
 (submitted: May 9, 2016)
  • Immunogenicity assessed by GMT of HI antibody against the against heterologous strains [ Time Frame: 21 days after injection ]
    Immunogenicity will be assessed by GMT of HI antibody against the against heterologous strains
  • Immunogenicity assessed by GMT of microneutralization (MN) antibody against the against homologous and heterologous strains [ Time Frame: 21 days after injection ]
    Immunogenicity will be assessed by GMT of microneutralization (MN) antibody against the against homologous and heterologous strains
  • Immunogenicity assessed by GMT of single radial hemolysis (SRH) antibody against the against homologous and heterologous strains [ Time Frame: 21 days after injection ]
    Immunogenicity will be assessed by GMT of single radial hemolysis (SRH) antibody against the against homologous and heterologous strains
  • Immunogenicity assessed by cell-mediated immune (CMI) response against the against homologous and heterologous strains [ Time Frame: 21 days after injection ]
    Immunogenicity will be assessed by cell-mediated immune (CMI) response against the against homologous and heterologous strains
  • Incidence of Solicited Local and Systemic Reactions [ Time Frame: 21 days after injection ]
  • Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: 21 days after injection ]
  • Incidence of Abnormal Clinical Laboratory Tests [ Time Frame: 3 days after injection ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults
Official Title  ICMJE Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Adults 18-64 Years of Age
Brief Summary This Phase 2 Quadrivalent VLP Vaccine study is intended to replicate and extend the immunogenicity and safety results obtained in earlier Phase 1-2 and Phase 2 studies. The study is being conducted to demonstrate that the immunogenicity profile of the Quadrivalent VLP Vaccine meets the US Center for Biologics Evaluation and Research (CBER) licensure criteria. The study will also help to define the optimal dose, establish potential competitive advantages, and support the design of future studies.
Detailed Description

This randomized, observer-blind, multicenter, Phase 2 study will be conducted at multiple sites across the United States and Canada.

The influenza strain composition of the Quadrivalent VLP Vaccine used in this study includes 2 influenza A virus strains (A/California/7/2009 [H1N1] and A/Switzerland/9715293/2013 [H3N2]) and 2 influenza B virus strains (B/Phuket/3073/2013 [Yamagata lineage] and B/Brisbane/60/2008 [Victoria lineage]), based on the 2015-2016 recommended World Health Organization (WHO) strains for vaccination in the Northern hemisphere.

Approximately 900 healthy subjects will be randomized in a 1:1:1 ratio to 1 of 3 parallel treatment groups. Subjects in each group will be stratified into 2 age strata: 18 to 49 years and 50 to 64 years in a 2:1 ratio.

Subjects will receive one intramuscular (IM) injection of their assigned vaccine:

  • 15 µg/strain of Quadrivalent VLP Vaccine, or
  • 30 µg/strain of Quadrivalent VLP Vaccine, or
  • 15 µg/strain of the licensed and commercially available quadrivalent vaccine FluLaval® Tetra.

Subjects will participate in this study for approximately 8 months, during which 5 visits will be scheduled, and phone contact will be made on Day 1, Day 8, and every 2 months thereafter for up to 6 months post-Day 21 visit (Day 201). Safety laboratory assessments will be performed at Screening, on Day 3 and within 48 hours of Day 3 results availability, for grade 3 or grade 4 abnormalities or if deemed necessary by the investigator or early termination.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Prevention
Condition  ICMJE
  • Virus Diseases
  • RNA Virus Infections
  • Respiratory Tract Diseases
  • Respiratory Tract Infections
Intervention  ICMJE
  • Biological: 15 µg/strain of Quadrivalent VLP Vaccine
    Single dose of non-adjuvanted Quadrivalent VLP Vaccine
  • Biological: 30 µg/strain of Quadrivalent VLP Vaccine
    Single dose of non-adjuvanted Quadrivalent VLP Vaccine
  • Biological: 15 µg/strain of the licensed quadrivalent vaccine
    Single dose of the licensed quadrivalent vaccine
    Other Names:
    • FluLaval® Tetra
    • FluLaval® Quadrivalent
Study Arms  ICMJE
  • Experimental: 15 µg/strain of Quadrivalent VLP Vaccine
    Intervention: Biological: 15 µg/strain of Quadrivalent VLP Vaccine
  • Experimental: 30 µg/strain of Quadrivalent VLP Vaccine
    Intervention: Biological: 30 µg/strain of Quadrivalent VLP Vaccine
  • Active Comparator: 15 µg/strain of the licensed quadrivalent vaccine
    Intervention: Biological: 15 µg/strain of the licensed quadrivalent vaccine
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: May 9, 2016)
900
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE November 26, 2016
Actual Primary Completion Date May 17, 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Subjects must be able to read, understand, and sign the informed consent form (ICF); complete study-related procedures; and communicate with the study staff at visits and by phone.
  2. Subjects are considered by the Investigator to be reliable and likely to cooperate with the assessment procedures and be available for the duration of the study.
  3. Male and female subjects must be 18 to 64 years of age, inclusive, at Screening (Visit 1).
  4. Subjects have a body mass index (BMI) of ≥ 18.0 and ≤ 32.4 kg/m2 at Day 0.
  5. Subjects must be in good general health prior to study participation (no more than 30 days prior to study vaccine administration) with no clinically relevant abnormalities that could jeopardize subject safety or interfere with study assessments as assessed by the Principal Investigator or sub-Investigator (thereafter referred as Investigator) and determined by medical history, physical examination, biochemistry, hematology, and urinalysis. Note: Subjects with a pre-existing chronic disease will be allowed to participate if the disease is stable and, according to the Investigator's judgment, the condition is unlikely to confound the results of the study or pose additional risk to the subject by participating in the study. Stable disease is generally defined as no new onset or exacerbation of pre-existing chronic disease 6 months prior to immunization. Based on the Investigator's judgment, a subject with more recent stabilization of a disease could also be eligible.
  6. Female subjects must have a negative serum pregnancy test result at Screening (Visit 1) and a negative urine pregnancy test at Randomization prior to immunization.
  7. Female subjects of childbearing potential must use an effective method of contraception for 1 month prior to immunization and agrees to continue employing adequate birth control measures for at least 60 days post-immunization. Moreover, she must have no plan to become pregnant for at least 2 months post-immunization. Abstinent subjects should be asked what method(s) they would use, should their circumstances change, and subjects without a well-defined plan should be excluded.

    The following relationship or methods of contraception are considered to be effective:

    • Hormonal contraceptives (e.g., injectable, topical [patch], or estrogenic vaginal ring);
    • Intra-uterine device with or without hormonal release;
    • Male partner using a condom plus spermicide or sterilized partner (at least 1 year prior to immunization);
    • Credible self-reported history of heterosexual abstinence until at least 60 days postimmunization;
    • Female partner.
  8. Non-childbearing females are defined as:

    • Surgically-sterile (defined as bilateral tubal ligation, hysterectomy or bilateral oophorectomy performed more than 1 month prior to immunization); or
    • Post-menopausal (absence of menses for 24 consecutive months and age consistent with natural cessation of ovulation).

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded from participating in this study:

  1. According to the Investigator's opinion, history of significant acute or chronic, uncontrolled medical or neuropsychiatric illness. "Uncontrolled" is defined as:

    • Requiring a new medical or surgical treatment within one month prior to study vaccine administration;
    • Requiring a change in medication dosage during one month prior to study vaccine administration due to uncontrolled symptoms or drug toxicity, or for chronic diseases, significant change in medication dosage within 6 months prior to study vaccine administration based upon the investigator's judgment (elective dosage adjustments in stable subjects are acceptable).
  2. Any medical or neuropsychiatric condition or any history of excessive alcohol use or drug abuse which, in the Investigator's opinion, would render the subject unable to provide informed consent or unable to provide valid safety observations and reporting.
  3. Any autoimmune disease other than hypothyroidism on stable replacement therapy or any confirmed or suspected immunosuppressive condition or immunodeficiency including known or suspected human immunodeficiency virus (HIV), Hepatitis B or C infection, or the presence of lymphoproliferative disease.
  4. Administration or planned administration of any non-influenza vaccine within 30 days prior to randomization up to blood sampling at Day 21. Immunization on an emergency basis will be evaluated case-by-case by the Investigator.
  5. Administration of any adjuvanted or investigational influenza vaccine within 1 year prior to randomization or planned administration prior to the completion of Day 201.
  6. Administration of any 'standard', non-adjuvanted influenza vaccine (e.g., live attenuated trivalent/quadrivalent inactivated influenza vaccine Intranasal or split trivalent/quadrivalent inactivated influenza vaccine by either intradermal or intramuscular [IM] route) within 6 months prior to randomization and up to completion of Day 21 visit.
  7. Use of any investigational or non-registered product within 30 days or 5 half-lives, whichever is longer, prior to randomization or planned use during the study period. Subjects may not participate in any other investigational or marketed drug study while participating in this study until Day 201 visit.
  8. Treatment with systemic glucocorticoids at a dose exceeding 10 mg of prednisone per day, or equivalent for more than 7 consecutive days or for 10 or more days in total, within one month of study vaccine administration, any other cytotoxic or immunosuppressant drug, or any immunoglobulin preparation within 3 months of vaccination and until the completion of Day 21 visit. Low doses of nasal or inhaled glucocorticoids are allowed. Topical steroids are permitted.
  9. Any significant disorder of coagulation including treatment with warfarin derivatives or heparin. Persons receiving prophylactic anti-platelet medications (e.g., low-dose aspirin [no more than 325 mg/day]), and without a clinically apparent bleeding tendency are eligible. Subjects treated with new generation drugs that do not increase the risk of intramuscular bleeding (e.g., clopidogrel) are also eligible.
  10. History of allergy to any of the constituents of the Quadrivalent VLP vaccine (including H1N1, H3N2, B/Bris, and B/Phuket), to any components of the licensed quadrivalent vaccine, or tobacco allergy.
  11. History of anaphylactic allergic reactions to any food, medication, or bee sting.
  12. Any history of serious asthma (e.g., status asthmaticus, hospitalization for asthma control) or recurrent asthma episodes requiring medical attention in the last 3 years (≥ 1 episode/year)
  13. Continuous use of antihistamines in the last 4 weeks prior to immunization or use of antihistamines 48 hours prior to study immunization.
  14. Use of prophylactic medications (e.g. acetaminophen/paracetamol, aspirin, naproxen, or ibuprofen) within 24 hours of randomization to prevent or pre-empt symptoms due to vaccination. Subject discovered to have taken a prophylactic medication within the 24 hours prior to planned randomization must be delayed until at least the 24 hours period is met.
  15. Have a rash, dermatological condition, tattoos, muscle mass, or any other abnormalities at injection site that may interfere with injection site reaction rating.
  16. Have received a blood transfusion within 90 days prior to study vaccination.
  17. If female subject, have a positive or doubtful pregnancy test result prior to immunization or lactating females.
  18. Have abnormal vital signs defined as: systolic Blood Pressure (BP) > 140 mmHg and/or diastolic BP ≥ 90mmHg, heart rate ≤ 45 beats/min and ≥ 100 beats/min. Even if one or more vital signs are out of the acceptable ranges, a subject may still be included in the study based on Investigator's judgment (e.g. a resting heart rate ≤ 45 in highly-trained athletes). Presence of any febrile illness (including oral temperature (OT) ≥ 38.0 ˚C within 24 hours prior to immunization). Such subjects may be re-evaluated for enrolment after resolution of illness.
  19. Cancer or treatment for cancer within 3 years of study vaccine administration. Persons with a history of cancer who are disease-free without treatment for 3 years or more are eligible. Persons with treated and uncomplicated basal cell carcinoma of the skin are eligible. Person with non-treated, non-disseminated local prostate cancer are eligible.
  20. Identified as an Investigator or employee of the Investigator or clinical site with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study or any employees of Medicago.
  21. Subject with a history of Guillain-Barre Syndrome.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 64 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02768805
Other Study ID Numbers  ICMJE CP-Q14VLP-009
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Medicago
Study Sponsor  ICMJE Medicago
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Pierre Lachance, MD Centre de Recherche St-Louis, Quebec, Canada
Principal Investigator: Marc Dionne, MD Équipe de recherche en vaccination du CHU de Québec-Université Laval (CHU), Quebec, Canada
Principal Investigator: Michael Libman, MD McGill University Health Center - Vaccine Study Center (MUHC), Montreal, Canada
Principal Investigator: Trevor Wesson, MD Diex Research Montreal, Montreal, Canada
Principal Investigator: Ginette Girard, MD Diex Research Sherbrooke, Sherbrooke, Canada
Principal Investigator: Deepen Patel, MD Topstone Research, Toronto, Canada
Principal Investigator: Diane Krieger, MD Miami Research Associates (MRA), Miami (FL), USA
Principal Investigator: David Seiden, MD Broward Research Group (BRG), Hollywood (FL), USA
Principal Investigator: Suchet R Patel, MD Regional Clinical Research (RCR), Endwell (NY), USA
PRS Account Medicago
Verification Date June 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP